That Pharmacyclics Inc./Janssen Biotech Inc. are launching their hematological cancer drug ibrutinib with a patient financial support program is to be expected. But the multiple approaches and tandem programs being offered show how extensive these programs must be as drugs with six-figure price tags grapple with reimbursement realities.
Imbruvica (ibrutinib) is the first Bruton’s tyrosine kinase inhibitor and the second breakthrough therapy to receive FDA approval. It was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?